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WelcometoPLoSClinicalTrials.Thisnew
journal is devoted to providing an
unbiased, peer-reviewed forum for trial
resultsinallﬁeldsofmedicineandpublic
health. But why is a new journal needed?
Intheworldofclinicaltrials,thecurrent
publishingsystemdoesnotworkinthebest
interests of patients, clinicians, or health
policymakers. All these groups of people
should be able to base their decisions on
good-quality systematic overviews of all
the available evidence. Thorough
systematic review requires access to and
careful evaluation of all the primary
research studies that address the question
of interest, and robust mechanisms
are therefore needed for unbiased
dissemination of the results of clinical
research. However, bias is known to exert
aneffectatvirtuallyeverystage,fromstudy
concept and design [1] to write-up and
publication [2,3]. In an Essay published as
part of the ﬁrst group of papers in PLoS
Clinical Trials, David Korn and Susan
Ehringhaus [4] identify an urgent need
for higher standards, and discuss why in
particular all those engaged in trial
sponsorship and conduct must work
toward universal disclosure of study
results. Current efforts toward universal
prospective registration of trials [5] will
contribute signiﬁcantly toward this goal.
Registrationensuresthattrialsarepublicly
knownfromthestart,encouragingfulland
transparent reporting.
So what is PLoS Clinical Trials doing to
achieve the goal of reducing bias? The
journal is a crucial step toward making
peer review and publication more
impartial. Reviewers and academic
editors for PLoS Clinical Trials are asked
to focus on whether a trial’s methods are
appropriate and ethical, the analyses
sound, and the interpretation accurate.
Provided that these things are done, the
trial will be published, irrespective of
whether a prespeciﬁed analysis adds truly
novel results, refutes something that was
previously thought to be the case, or
provides conﬁrmatory data.
The results are reported in a structured
format based on the consolidated
standards of reporting trials
(CONSORT) guidelines [6], making it
easy for readers to understand what was
done and what the results mean. Editorial
summaries written by editorial staff,
based on the comments of academic
editors and expert reviewers, will
accompany each paper, and will provide
an important mechanism for describing
without frills what was found and what
the results add to the evidence. And, of
course, open-access publication ensures
that trial results will be available
immediately to all for reading, reuse, or
reanalysis through the Web site, as well as
PubMed Central. PLoS Clinical Trials also
provides investigators and funders with a
peer-reviewed journal publication—a just
reward for the huge investment that can
be involved in running trials.
In the short period, since PLoS Clinical
Trials was announced, submissions have
arrived from around the world, including
Australia, Belgium, The Gambia,
Germany, Mozambique, the Netherlands,
Spain, Uganda, the United Kingdom, and
the United States. The journal’s scope
encompasses trials testing the effects of
all types of interventions related to health
care. So far, submissions to the journal
have reﬂected this diversity, and have
included not only pharmaceutical studies
but also trials testing experimental
vaccines, surgical procedures, and
complex and educational interventions.
The valuable guidance and support of the
PLoS Clinical Trials advisory board,
editorial board, and statisticians have
helped to shape the journal’s launch, but
we intend to continue evolving in
response to feedback from you and the
broader community.
Perhaps you agree with the proposals
put forward by Smith and Roberts [7],
that the future of trials publishing should
not involve medical journals. Instead,
they propose that trial protocols and
complete datasets should be published
on the Web. There, the community can
comment on trial design and contribute
toward appropriate analysis of the results.
By running only prespeciﬁed analyses,
and by removing interpretation, except
in the context of the overall evidence,
spin and bias of individual trial results are
eliminated. The Global Trial Bank (GTB)
[8] will offer such a solution for the
future, and PLoS Clinical Trials is
partnering with GTB to make universal
access to computable trial data a reality.
So, if you share our vision for an
unbiased clinical research literature, we
invite you to contribute to PLoS Clinical
Trials. You can comment on the articles
that we’ve published and send your
presubmission inquiries via the Web site
at http://www.plosclinicaltrials.org. But we
also welcome comments and ideas—
however radical—for the journal’s
future. We look forward to hearing from
you at plosclinicaltrials@plos.org. “
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